Geron to Announce First Quarter 2022 Financial Results on May 9, 2022

Rhea-AI Summary

Geron Corporation (NASDAQ: GERN) will release its first quarter 2022 financial results on May 9, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET the same day to discuss the results and recent developments. Geron is focused on developing imetelstat, a first-in-class telomerase inhibitor, currently in two Phase 3 trials: IMerge for lower risk myelodysplastic syndromes and IMpactMF for refractory myelofibrosis. The press release and webcast details are accessible on their website.

Positive

• Conducting two Phase 3 clinical trials for imetelstat, indicating significant progress in drug development.

Negative

• None.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN) today announced that it will release its first quarter 2022 financial results after the market closes on Monday, May 9, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent highlights at 4:30 p.m. ET the same day.

A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.

Participants may access the webcast by registering online using the following link, https://conferencingportals.com/event/SmvlMvWL. Participants that are unable to register online can access the conference call via telephone by dialing domestically +1 (888) 330-2434 or internationally +1 (240) 789-2725. The conference ID is 67335.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005041/en/

Aron Feingold

Investor and Media Relations

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

When will Geron Corporation release its financial results for Q1 2022?

Geron Corporation will release its financial results on May 9, 2022, after market close.

What time is the conference call for Geron's Q1 2022 financial results?

The conference call is scheduled for 4:30 p.m. ET on May 9, 2022.

What are the focus areas of Geron Corporation's clinical trials?

Geron is currently focused on two Phase 3 trials for imetelstat in lower risk myelodysplastic syndromes and refractory myelofibrosis.